Mitochondrial Gene Therapy Passes Final U.K. Vote
By Gretchen Vogel,
Science Insider
| 02. 24. 2015
[Quotes CGS's Marcy Darnovsky]
Untitled Document
The United Kingdom’s House of Lords has approved legislation to allow a new type of in vitro fertilization (IVF) that would replace faulty DNA, preventing certain types of genetic diseases. The vote follows the House of Commons approval of the measure on 3 February, making the United Kingdom the first country to explicitly allow the procedure, which would combine DNA from two biological parents and an egg donor.
The technique will be allowed under fairly tight regulation: Researchers who wish to offer the service to couples still must apply for and receive a license from the country’s Human Fertilisation and Embryology Authority.
The technique, called mitochondrial DNA replacement therapy, would allow women who have mutations in the DNA of their mitochondria, the organelles that provide chemical energy for cells, to have genetically related children who don’t carry the mutations. It is controversial, however, because it would modify the DNA of an embryo in a way that could be passed on to future generations.
People who have faulty mitochondria can experience a variety of symptoms, including heart problems...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...